Molecular therapy for Pulmonary Hypertension (PAH): Endothelin-1 inhibits pulmonary hypertension via induction of PDLIM5, 10/February/2015, 23.25

Molecular therapy for Pulmonary Hypertension (PAH): Endothelin-1 inhibits pulmonary hypertension via induction of PDLIM5, 10/February/2015, 23.25

Molecular therapy for Pulmonary Hypertension (PAH): Endothelin-1 inhibits pulmonary hypertension via induction of PDLIM5, 10/February/2015, 23.25 150 150

Idea Proposed/Formulated by: Dr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Significance: This study suggests, for the first time, that Endothelin-1, by suppressing the expression of its target gene, it may increase the expression of PDLIM5. Thereby, it may inhibit pulmonary hypertension. Together, pharmacological formulations encompassing “Endothelin-1 or its activators“ may be used to treat pulmonary arterial hypertension (PAH).

Amount: $ 300*

Undisclosed information: How Endothelin-1  increases the expression of PDLIM5

To cite: Boominathan, Molecular therapy for Pulmonary Hypertension (PAH): Endothelin-1 inhibits pulmonary hypertension via induction of PDLIM5, 10/February/2015,  23.25,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Share
Start Typing